Traditional Biologics
Proteins, peptides, and DNA are all made in either mammalian or microbial organisms and regulated as biologics. Here we include antibody–drug conjugates to round out this exciting sector of the pharmaceutical industry.
The new workhorses of the pharma industry account for half of new U.S. drug approvals in the past 5 years. Learn the basics of manufacturing these complex molecules and how manufacturers are continuously innovating to provide increasingly sophisticated molecules on tighter timelines and at lower cost. New analytical technologies and changing regulatory standards are also driving innovation. Improvements in manufacturing and testing traditional biologics have paved the way for next-gen versions such as antibody-drug conjugates and multi-specific proteins. In addition to analyzing the landscape of GLP-1 and insulin-based trials, we’ve performed our own analysis of clinical trials involving an ADC or bispecific antibody to support our take on the industry trends.
